FDA approves Novartis Sonidiegib for the treatment of advanced basal cell carcinoma (laBCC) July 27, 2015 Source: Novartis On July 24, Novartis announced that the FDA approved its Sonidegib (LDE225) for the treatment of advanced basal cell carcinoma. LDE225 is currently undergoing clinical trials for a variety of conditions, including myelofibrosis, leukemia and solid tumors such as pancreatic cancer, breast cancer. And non-small cell lung cancer, in addition to this drug and tyrosine kinase inhibitors such as Novartis's chronic myeloid leukemia drug Nilotinib combined drug research is also underway. Although patients with melanoma-type skin cancer can see a series of new treatments on the R&D line, such as Bristol-Myers Squibb's Ipilimumab, First Triad/Roche's Willofini and GlaxoSmithKline Mekinist (trametinib) and Tafinlar (dabrafenib) are already available and can improve survival, but BCC patients have not been so lucky. Melanoma is generally considered to be more dangerous, but BCC is the most common form of skin cancer, accounting for 80% of all non-melanoma cases. If the disease reaches advanced stage, it can be extremely damaging and life-threatening. In addition, the incidence of BCC increases by about 10% per year. Vitamins,Vitamin B5,Vitamin D,Vitamin B4,Vitamin K PYSON Co. ,Ltd. , https://www.pysonbio.com